BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

607 related articles for article (PubMed ID: 21906738)

  • 1. Plasma levels of soluble receptor for advanced glycation end products (sRAGE) and proinflammatory ligand for RAGE (EN-RAGE) are associated with carotid atherosclerosis in patients with peritoneal dialysis.
    Kim JK; Park S; Lee MJ; Song YR; Han SH; Kim SG; Kang SW; Choi KH; Kim HJ; Yoo TH
    Atherosclerosis; 2012 Jan; 220(1):208-14. PubMed ID: 21906738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating levels of soluble receptor for advanced glycation end product are inversely associated with vascular calcification in patients on haemodialysis independent of S100A12 (EN-RAGE) levels.
    Kim HS; Chung W; Kim AJ; Ro H; Chang JH; Lee HH; Jung JY
    Nephrology (Carlton); 2013 Dec; 18(12):777-82. PubMed ID: 24124651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in non-diabetic subjects with pre-mature coronary artery disease.
    Mahajan N; Malik N; Bahl A; Dhawan V
    Atherosclerosis; 2009 Dec; 207(2):597-602. PubMed ID: 19576587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma S100A12 and soluble receptor of advanced glycation end product levels and mortality in chronic kidney disease Stage 5 patients.
    Isoyama N; Leurs P; Qureshi AR; Bruchfeld A; Anderstam B; Heimburger O; Bárány P; Stenvinkel P; Lindholm B
    Nephrol Dial Transplant; 2015 Jan; 30(1):84-91. PubMed ID: 25074436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low plasma levels of the soluble receptor for advanced glycation end products in HIV-infected patients with subclinical carotid atherosclerosis receiving combined antiretroviral therapy.
    Jeong SJ; Kim CO; Song YG; Baek JH; Kim SB; Jin SJ; Ku NS; Han SH; Choi JY; Lee HC; Kim JM
    Atherosclerosis; 2011 Dec; 219(2):778-83. PubMed ID: 21872861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do elevated plasma S100A12 levels predict atherosclerosis in peritoneal dialysis patients?
    Yayar O; Eser B; Buyukbakkal M; Erdogan B; Ercan Z; Merhametsiz O; Haspulat A; Kali A; Yildirim T; Canbakan B; Ayli MD
    Ren Fail; 2015 Jun; 37(5):845-50. PubMed ID: 26016405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two soluble isoforms of receptors for advanced glycation end products (RAGE) in carotid atherosclerosis: the difference of soluble and endogenous secretory RAGE.
    Moriya S; Yamazaki M; Murakami H; Maruyama K; Uchiyama S
    J Stroke Cerebrovasc Dis; 2014; 23(10):2540-2546. PubMed ID: 25282185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in type 1 diabetes.
    Katakami N; Matsuhisa M; Kaneto H; Matsuoka TA; Sakamoto K; Yasuda T; Umayahara Y; Kosugi K; Yamasaki Y
    Atherosclerosis; 2009 May; 204(1):288-92. PubMed ID: 18926539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated Circulating S100A12 Associates with Vascular Disease and Worse Clinical Outcome in Peritoneal Dialysis Patients.
    Isoyama N; Machowska A; Qureshi AR; Yamamoto T; Anderstam B; Heimburger O; Barany P; Stenvinkel P; Lindholm B
    Perit Dial Int; 2016; 36(3):269-76. PubMed ID: 26493750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between sRAGE, esRAGE levels and vascular inflammation: analysis with (18)F-fluorodeoxyglucose positron emission tomography.
    Yang SJ; Kim S; Hwang SY; Kim TN; Choi HY; Yoo HJ; Seo JA; Kim SG; Kim NH; Baik SH; Choi DS; Choi KM
    Atherosclerosis; 2012 Feb; 220(2):402-6. PubMed ID: 22137663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of circulating soluble receptor for advanced glycation end products (sRAGE) and the proinflammatory RAGE ligand (EN-RAGE, S100A12) on mortality in hemodialysis patients.
    Nakashima A; Carrero JJ; Qureshi AR; Miyamoto T; Anderstam B; Bárány P; Heimbürger O; Stenvinkel P; Lindholm B
    Clin J Am Soc Nephrol; 2010 Dec; 5(12):2213-9. PubMed ID: 20847094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low glucose degradation product peritoneal dialysis regimen is associated with lower plasma EN-RAGE and HMGB-1 proinflammatory ligands of receptor for advanced glycation end products.
    Opatrna S; Popperlova A; Kalousová M; Zima T
    Ther Apher Dial; 2014 Jun; 18(3):309-16. PubMed ID: 24965297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Higher levels of the soluble receptor for advanced glycation end products and lower levels of the extracellular newly identified receptor for advanced glycation end products were associated with lipid-lowering drugs in patients with type 1 diabetes: a comparative cross-sectional study.
    Melin EO; Dereke J; Hillman M
    Lipids Health Dis; 2020 Oct; 19(1):223. PubMed ID: 33054750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High Plasma sRAGE (Soluble Receptor for Advanced Glycation End Products) Is Associated With Slower Carotid Intima-Media Thickness Progression and Lower Risk for First-Time Coronary Events and Mortality.
    Grauen Larsen H; Marinkovic G; Nilsson PM; Nilsson J; Engström G; Melander O; Orho-Melander M; Schiopu A
    Arterioscler Thromb Vasc Biol; 2019 May; 39(5):925-933. PubMed ID: 30917679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating S100A12 Levels Are Associated with Progression of Abdominal Aortic Calcification in Hemodialysis Patients.
    Choi BH; Ro H; Jung ES; Kim AJ; Chang JH; Lee HH; Chung W; Jung JY
    PLoS One; 2016; 11(2):e0150145. PubMed ID: 26914918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating levels of soluble receptor for advanced glycation end products and ligands of the receptor for advanced glycation end products in patients with acute liver failure.
    Basta G; Del Turco S; Navarra T; Lee WM;
    Liver Transpl; 2015 Jun; 21(6):847-54. PubMed ID: 25825217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein.
    Basta G; Sironi AM; Lazzerini G; Del Turco S; Buzzigoli E; Casolaro A; Natali A; Ferrannini E; Gastaldelli A
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4628-34. PubMed ID: 16926247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Associations between Soluble Receptor for Advanced Glycation End Products (sRAGE) and S100A12 (EN-RAGE) with Mortality in Long-term Hemodialysis Patients.
    Jung ES; Chung W; Kim AJ; Ro H; Chang JH; Lee HH; Jung JY
    J Korean Med Sci; 2017 Jan; 32(1):54-59. PubMed ID: 27914132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum soluble receptor for advanced glycation end products levels and aortic augmentation index in early rheumatoid arthritis--a prospective study.
    Tam LS; Shang Q; Li EK; Wong S; Li RJ; Lee KL; Leung YY; Ying KY; Yim CW; Kun EW; Leung MH; Li M; Li TK; Zhu TY; Chui RK; Tseung L; Yu SL; Kuan WP; Yu CM
    Semin Arthritis Rheum; 2013 Feb; 42(4):333-45. PubMed ID: 22920235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum levels of soluble receptor for advanced glycation end products and of S100 proteins are associated with inflammatory, autoantibody, and classical risk markers of joint and vascular damage in rheumatoid arthritis.
    Chen YS; Yan W; Geczy CL; Brown MA; Thomas R
    Arthritis Res Ther; 2009; 11(2):R39. PubMed ID: 19284577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.